Two phase III clinical trials was cancelled last week after it was found that they are not likely to meet the primary endpoints.
The trial ATTRACT-1 testing the drug ASA404 in patients with lung cancer previously untreated, advanced non-small cell (NSCLC), ASA404, vadimezan, also known as is a new type of angiogenesis inhibitor is called vascular. trial was stopped after a planned interim analysis showed
No comments:
Post a Comment